KARI HURT: Open Payments
NPI 1669943320 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$895 in 52 payments from 16 companies in 2025. Trend: 2023 $287 · 2024 $505 · 2025 $895
Food & beverage: $895
| Company | Payments | Amount |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 24 | $180 |
| Madrigal Pharmaceuticals | 3 | $149 |
| Gilead Sciences, Inc. | 5 | $127 |
| Mirum Pharmaceuticals, Inc. | 3 | $73 |
| Ipsen Biopharmaceuticals, Inc | 3 | $69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $63 |
| Azurity Pharmaceuticals, Inc. | 2 | $46 |
| Ethicon US, LLC | 1 | $43 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
Products named: OCALIVA, REZDIFFRA, Livmarli, IQIRVO, XIFAXAN, VISTASEAL, PURIFIED CORTROPHIN GEL, GATTEX.
Industry payments across GA — which companies pay providers there.
